# National Transfusion Advisory Group





NTAG

# SHIFTING THE PARADIGM THROUGH QUALITY IMPROVEMENT

Dr Joan Power
Consultant Haematologist
Clinical Lead Advisor for Transfusion

Pre Transfusion crisis intervention

Blood Transfusion has strong legal framework for Quality and Haemovigilence (HV) Arising from blood scandals and ensuing enquiries

Pathway needed now to develop national sustained cycle of Quality Healthcare improvement from this base

**Legal framework - EU Directives** 

(Mother Directive) 2002/98/EC

Setting standards of Quality And Safety for the collection, testing, processing, storage and distribution of human blood and blood components



SI 360 of 2005 European Communities Quality and Safety of Human Blood and Blood Components Regulations 2005

Second Technical (Daughter) Directive 2005/61/EC

Traceability requirements and notification of Serious adverse reactions and events (Haemovigilance)


SI 547of 2006 - AMLBB minimum requirements for use in conjunction with ISO 15189 standard

However does not include clinical SAE

Haemovigilance (mature) definition:

"set of surveillance procedures covering the whole transfusion chair to collect & assess information on unexpected/undesirable effects Serious adverse events (SAE), Serious adverse reactions (SAR) resulting from the therapeutic use of labile blood components and to prevent their occurrence/recurrence" With mandatory and voluntary elements

UK HV system 'Serious Hazards of Transfusion' SHOT



Irish HV system- NHO

Reporting trends 2008-2018





Deaths	TACO	Age >69	Clinical Error related
9	9	8	<ul><li>3 (dilute sample-wrong Hb, rate too fast,</li><li>2 units transfused where 1 prescribed)</li></ul>

Róisín Brady

NHO- 2020 SAE/SAR TRENDS

Total Reports (inc anti-D Ig events) - 219

TACO - 30 (14%)

age	18-50	51-70	>70
N=	2	8	20

Clinical outcome	Death possibly related	Serious sequelae	Minor sequelae
N=	1	2	3

Following single unit transfused

N=17

Error associated	
N=2	4 units transfused for prescription of 3 2 units administered too quickly

#### **WBIT**

WBIT 2020	EBTS in hospital	MNCMS in hospital	Total electronic system
N=79	55	18	In hospital 73
(N=48 2019)	EBTS in use 36	MNCMS in use 15	In use 51


Site of first error	labelling	sampling	Admission clerking	other
N=	38	23	5	1

COVID- 19 related		Distraction at labelling	transposition	Error in handwritten sample
N=7	3	1	1	2


18 potentially ABO incompatible

Figure 3.5: Cumulative data for SHOT categories 1996-2019 n=23341

SHOT




<sup>\*</sup>Data on alloimmunisation has not been collected since 2015




Sources of data: Many of these are found online in the UK office for national statistics. Red outline indicates SHOT data, blue outline indicates data from other sources. ISTARE is the International Haemovigilance Network database for the surveillance of adverse reactions and events in donor and recipients. Viral transmissions denote risk of infection, not deaths. HCV=hepatitis C virus; HIV=human immunodeficiency virus; HBV=hepatitis B virus. A full list of sources is available in supplementary information on the SHOT website <a href="https://www.shotuk.org">www.shotuk.org</a>.

# LEARNING FROM ADVERSE EVENTS -CHANGES IN THE BLOOD CENTRE




SHOT



107-Intrauterine transitiation.

Learning from Adverse Events -changes in the blood centre




Venepuncture site decontamination, deviation 1st 30 ml donation, enhanced testing

#### Trends in Clinical errors - interventions needed

Figure 2.7: Trend of error reports from different departments





Developing a National Framework Clinical lead advisor appointed - Sept 2019 Network of Transfusion laboratories - by hospital level

**Transfusion laboratories structure.** There are 47 Hospital transfusion laboratories across the country. In addition these act as the transfusion laboratory support for a further 22 Hospitals and 6 Hospices. As expected, transfusion support differs significantly by the complexity of service delivered from each hospital-see Fig 1.




Figure 1 –

Red cell
and
platelet
usage
2018 by
hospital
Level/type

#### Turn data into intelligence? ROI 'single unit transfusion'

Hospital/Ref	Date	Denominator	Single Unit Transfusion Rate
Hospital			
National Blood Strategy Implementation Group 24/64 acute hospitals reported transfusions on the day (67 RC Trx episodes with 201 units trx'd to 51 pts)	National Study Day Wednesday 19/02/2002	Peri-op (within 48 hrs)  RC transfusion 19 <sup>th</sup> June (Vs NBUG Guideline, Jan '01)	12% of RC transfused
Hospital A Dublin 4,500 RBC	Jul-Dec 2016	Trx within 24 hrs	40% of RC transfused
		Haematology pts (45% of all use) within 24 hrs	32% of RC transfused (88% double unit no inter-unit Hb check)
Hospital B Cork 1,148 RBC	Jan-Feb 19 <sup>th</sup> 2018	Bleeding & non-bleeding pts in a single transfusion episode - within 48 hrs	13% of transfusion episodes
		- within 72 hrs	9.1% of transfusion episodes
Hospital C Cork 133 crossmatches	Jan-June 2018	Per crossmatch	18% of crossmatches
Hospital D Limerick 71 pts./119 RCC 182 pts./330 RCC	May - August 2010	Per transfusion episode	46%, 51%
UK National comparative Audit-TACO audit	Mar-April 2017	157 hospitals 1,788 non-bleeding in-pts, all>60 yrs	37% of pts
- Haematology	July 2017	1091 out-pts 153 hospitals/3,830 RCC	21% of pts. 43% in pts. (2016 - 27%) 24% OPD (2016 - 13%)

ESTABLISHING THE NATIONAL TRANSFUSION ADVISORY GROUP

NTAG-INAUGURAL MEETING RCPI JAN 2020 ( TOR INC)

Engage in Guideline development in relation to Transfusion practice


Recommend Transfusion
Policies and Practices and
associated implementation
and accessibility pathways

Engage in National documentation development

Review national output data, including Patient Safety data from the NHO and other sources, and prioritise risk reduction measures.



NTAG 'PILLARS'
PROVIDE SUSTAINABILITY
ENSURE STAKEHOLDER REPRESENTATION




Irish Haematology Society Transfusion SIG ACSLM NTAG Scientific Committee National Haemovigilance SIG


#### 'BURNING PLATFORMS' - VIEW FROM JAN 2020

- O Rh D negative red cell components
- Patient safety WBIT, TACO, clinical application
- Patient Blood Management (PBM)
- National comparative Audit
- Life threatening Demand, Massive Haemorrhage,
   Mass Casualty event planning, Contingency

Structured approach to Test, Implement and Spread improvement across system



Effecting clinical change



COVID view March 2020

ApproachNTAG Multi
disciplinary
Working
Groups
for priority
interventions/
enhancements

Shortage preparedness

Use of CMV negative components

Patient information leaflet

Over-arching transfusion committees

eaflet

Patient blood management PBM

Procuring peripheral blood samples/WBIT

Transfusion support for FNP

Life threatening haemorrhage

Audit of transfusion support for COVID-19

infection

Education & training

Hospital Emergency Blood Management (EBM) Plan for Managing Shortages of Blood Components

National Transfusion Advisory Group NTAG proposed Framework

#### Authorised by:

Dr Joan Power, Clinical lead for Transfusion Prof Stephen Field, Medical & Scientific Director, IBTS Dr Michael Dockery, Chair, National Transfusion Advisory Group

#### Contents

- 1. Introduction & Development
- 2. Scope and Purpose
- 3. Terms and Abbreviations
- 4. Roles and Responsibilities
  - Appendix 1: IBTS Communication and Hospital Action
  - Appendix 2: Indication for transfusion in red cell shortage
  - Appendix 3: Proposed generic actions for hospitals at each phase

#### NTAG members

Dr. Michael Dockery, Dr. David Menzies, Ms. Roisin Brady, Dr. Valerie Broderick, Ms. Marina Cronin, Dr. Maeve Doyle, Prof. Stephen Field, Mr. Tony Finch, Ms. Grainne Flynn, Mr. Fergus Guilfoyle, Dr. Mary Keogan, Dr. Siobhan Kennelly, Mr. Richard Lodge, Dr. Peter McKenna, Dr. Kieran Morris, Mr. Damien Nee, Ms. Maureen Nolan, Ms. Norma O'Brien, Dr. Hilary O'Leary, Prof. Colm O'Morain, Mr. Kevin Sheehan/ Mr Barry Doyle,, Ms. Angela Petraska, Dr. Joan Power, Prof. Paul Ridgway, Mr. Stephen Roe, Dr. Jeremy Smith, Mr. Keith Synnott

The NTAG Plan will be considered for update Quarter one 2022.

National Transfusion Advisory Group NTAG; Guidelines for use of CMV antibody screened negative (CMV negative) cellular blood components (red cells, platelets and granulocytes) in the Irish healthcare setting. Version 01/September 2020

I. Hann<sup>1</sup>, C. Cantwell<sup>2</sup>, B. Doyle<sup>3</sup>, A. Hodgson<sup>4</sup>, AM. McCann<sup>5</sup>, K. Morris<sup>3</sup>, S. Ni Loinsigh<sup>6</sup>, M. Williams<sup>7</sup> and J. Power<sup>1</sup>.

<sup>1</sup>Irish Blood Transfusion Service, Munster Regional Transfusion Centre <sup>2</sup> Midlands Regional Hospital Mullingar <sup>3</sup> Irish Blood Transfusion Service, National Blood Centre <sup>4</sup> University Hospital Sligo & Mayo <sup>5</sup>St. James's Hospital Dublin <sup>6</sup> University Hospital Galway <sup>7</sup> Children's Health Ireland -Crumlin

#### Authorised by:

NTAG Working Group Chair: Prof I. Hann Clinical Lead Advisor for Transfusion: Dr J. Power Medical & Scientific Director Irish Blood transfusion service IBTS: Prof S. Field Chair National Transfusion Advisory Group NTAG: Dr M. Dockery.

#### CMV guidelines implementation planning - in progress

Guideline Implementation Recommendation barriers / enabler by patient cohort		Action / intervention / task to implement recommendation	Lead responsibility for delivery of	Timeframe for completion			Expected outcome and verification
			action	Year 1	Year 2	Year 3	
Allogeneic HCST Autologous HSCT	Barrier Allogeneic HSCT patient false CMV pos Enabler IHS ACSLM	<ul> <li>Ensure pre-transfusion         CMV serology at admission     </li> <li>Cycle of education, error id and audit</li> </ul>	• CLA	ſ	•	•	Outcomes: -Capture of Haem/onc patients transfused pre dx as IR report to HTC - capture of HSCT pts presenting as possible false pos ( passive anti-CMV ab)
Neonatal population	No change - IT flags	<ul><li>Education</li><li>National Prescription</li></ul>	cLA		I	0	
Pregnant women	No change -IT flags	<ul><li>Education</li><li>National Prescription</li></ul>			I		
foetuses	No change- It flags Requires issue from IBTS	<ul><li>Education</li><li>National Prescription</li></ul>	•		0	0	
Patients with HIV infection	Enablers Med scientists IT when available	<ul><li>Communication with ID colleagues Education</li><li>National Prescription</li></ul>	• CLA	l			
Solid organ transplant patients	Enabler  IHS ACSLM	<ul><li>Education</li><li>National Prescription</li></ul>	•				
Patients with immunodeficiency		<ul><li>Education</li><li>National Prescription</li></ul>	•				
Patients undergoing mgt for oncological disorders		<ul><li>Education</li><li>National Prescription</li></ul>	•				
Pts receiving granulocytes	Enabler - rarely transfused requires Cons Haem ok	<ul><li>Education</li><li>National Prescription</li></ul>	•	I			

National Transfusion
Advisory Group
Working Group: National
Patient Information Leaflet

Chair: Ms. Norma O'Brien & Dr. Kieran Morris Members: Ms Grainne Flynn, Mr Stephen Roe, Ms Joanne Scanlon, Ms Maureen Nolan, Ms Angela Petraska, Ms Miriam Kennedy, Dr Joan Power

- To develop a Stakeholder proposed, National Patient Information Leaflet for patients who may require transfusion component support in all hospitals country wide
- To update transfusion associated risks from NHO output
- To form the first part in the development of a national patient consenting process for transfusion

You may need a blood transfusion



This leaflet is designed to help you and your family understand what a blood transfusion is and how you can help make this a safer treatment for you.

Your doctor or nurse will explain if you are likely to need a blood transfusion and why. They will ask your permission to give you a blood transfusion. This means you share the decision to receive a blood transfusion. If you are unconscious, your doctor must treat you in your best interest. This includes giving you a transfusion without getting permission from you. (See 99)

#### This leaflet explains

1. What is a blood transfusion?2
2. Why would you need a blood transfusion?3
3. What are the risks of blood transfusion?3
4. Can you avoid a blood transfusion?5
5. How is a blood transfusion given?5
6. What are the different blood components?6
7. What should the patient do to ensure safe blood transfusion?6
8. Transfusion records – how long are they kept?7
9.What happens if you refuse a blood transfusion?7

#### 7. What should the patient do to ensure safe blood transfusion?

#### You have a vital role in making sure that you are identified correctly:

Make sure your identification information is correct: When the staff member is taking your sample to match your transfusion, make sure they know who you are. They should ask you (but not prompt) your:

- full name
- date of birth.

They should then check this against your hospital identification band. If the name or date of birth on your hospital identification band is incorrect, please tell your Healthcare staff

Please remind the clinical staff if you have:

- · had a reaction to a blood transfusion in the past
- been told you have special transfusion needs.

And you must let your healthcare <u>staff know</u> if you have any unpleasant feelings or symptoms. These can include:

- headache
- rash
- nausea
- vomiting
- fever
- chills
- shaking
- breathing difficulties.

These symptoms may occur during or after your transfusion and mostly within 24 hours. Healthcare staff are familiar with these and if needed, they will:

- stop the transfusion
- take blood tests and give you treatment for your symptoms.

Other safety measures in place: If you are transfused as an out-patient, your healthcare staff will give you a phone number to call the hospital in case you develop a reaction after you leave hospital.

If you have special transfusion needs (for example irradiated blood which is needed for some patients with cancer or receiving particular medication), it is recommended that you receive an lalert' card from your hospital. Also, the computer system in the hospital blood bank will have a warning flag to ensure that only blood that suits your special needs may be issued from the laboratory for you.



NTAG Patient Blood Management

#### National Transfusion Advisory Group NTAG

#### Governance

Dr Joan Fitzgerald, Consultant Haematologist Chair NTAG WG: PBM Dr Joan Power, Clinical lead for Transfusion Prof Stephen Field, MSD IBTS Dr Michael Dockery Chair NTAG

#### Working Group Scope - Draft 1 Objective

To develop a Stakeholder proposed NTAG Guideline for Patient Blood Management. Interim guidance may be issued. The NTAG PBM Guideline will be a controlled document(s) and the review process will be established. The Guideline will be authorised by the NTAG WG Chair, the Clinical Lead Advisor, M & SD IBTS and Chair NTAG.

Timely use of evidenced-based medical and surgical concepts designed to maintain Hb concentration, optimise haemostasis and minimise blood loss

Society for the Advancement of Blood Management, Professional definition Patient Blood Management, Sept.2012.:http://www.sabm.org//



# National Transfusion Advisory Group NTAG

#### Governance

Chair WG: Mr Morgan McMonagle Consultant General, Vascular and Trauma Surgeon,

University Hospital Waterford.

Dr Joan Power, Clinical Lead Advisor for Transfusion

Prof Stephen Field, Medical and Scientific Director IBTS

Dr Michael Dockery, Chair NTAG

#### Pre-'Transfusion crisis' intervention

Quality Improvement

Further national structures to support NTAG Working groups with Pathway to develop national sustained cycle of Healthcare improvement

#### Core elements;

- > NHO renewal governance, resourcing and data analysis
- Clinical data capture 'Turn data into intelligence'
  Well defined, consistent data item collection & recording
  (numerator, denominator, inclusions and exclusions) of high quality
- > Multi-annual national audit programme

#### PBM Message to patients

You should only receive a Blood Transfusion if it is necessary and you should have the opportunity to discuss the risks, benefits and alternatives with your doctor